Thompson Bradley George 4
4 · Enveric Biosciences, Inc. · Filed Sep 27, 2021
Insider Transaction Report
Form 4
Thompson Bradley George
Director
Transactions
- Award
Stock Options
2021-09-16+53,160→ 53,160 totalExercise: $0.94From: 2021-09-16Exp: 2026-04-05→ Common Stock (53,160 underlying)
Footnotes (4)
- [F1]Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.
- [F2]Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.
- [F3]Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.
- [F4]Received in exchange for options to acquire 200,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.